JP2012131808A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012131808A5 JP2012131808A5 JP2012024825A JP2012024825A JP2012131808A5 JP 2012131808 A5 JP2012131808 A5 JP 2012131808A5 JP 2012024825 A JP2012024825 A JP 2012024825A JP 2012024825 A JP2012024825 A JP 2012024825A JP 2012131808 A5 JP2012131808 A5 JP 2012131808A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- group
- chemical moiety
- clearance rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58607596A | 1996-01-11 | 1996-01-11 | |
| US08/586,075 | 1996-01-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9525384A Division JP2000503301A (ja) | 1996-01-11 | 1997-01-06 | 減少した正味の正電荷を有する抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012131808A JP2012131808A (ja) | 2012-07-12 |
| JP2012131808A5 true JP2012131808A5 (enExample) | 2013-04-04 |
Family
ID=24344206
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9525384A Pending JP2000503301A (ja) | 1996-01-11 | 1997-01-06 | 減少した正味の正電荷を有する抗体 |
| JP2012024825A Pending JP2012131808A (ja) | 1996-01-11 | 2012-02-08 | 減少した正味の正電荷を有する抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9525384A Pending JP2000503301A (ja) | 1996-01-11 | 1997-01-06 | 減少した正味の正電荷を有する抗体 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0873139B1 (enExample) |
| JP (2) | JP2000503301A (enExample) |
| KR (1) | KR100485240B1 (enExample) |
| AT (1) | ATE249243T1 (enExample) |
| AU (1) | AU730388B2 (enExample) |
| CA (1) | CA2242750C (enExample) |
| DE (1) | DE69724761T2 (enExample) |
| ES (1) | ES2206683T3 (enExample) |
| RU (1) | RU2219949C2 (enExample) |
| WO (1) | WO1997025069A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005047903A1 (en) * | 2003-11-07 | 2005-05-26 | Upstate Usa. Inc. | A method for generating antibody conjugates that preserves antigen recognition |
| WO2013184200A1 (en) * | 2012-06-05 | 2013-12-12 | Msm Protein Technologies | Human monoclonal antibodies against human chemokine receptor ccr7 |
| MX354303B (es) * | 2012-07-04 | 2018-02-23 | Hoffmann La Roche | Anticuerpos de anti-biotina y metodos de uso. |
| SG11201407420RA (en) | 2012-07-04 | 2015-02-27 | Hoffmann La Roche | Covalently linked antigen-antibody conjugates |
| EP2869837B1 (en) | 2012-07-04 | 2016-09-14 | F. Hoffmann-La Roche AG | Anti-theophylline antibodies and methods of use |
| BR112016014945A2 (pt) | 2014-01-03 | 2018-01-23 | F. Hoffmann-La Roche Ag | conjugado, formulação farmacêutica e uso |
| WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
| EP3089758B1 (en) | 2014-01-03 | 2021-01-27 | F.Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| FR2566271B1 (fr) * | 1984-06-20 | 1986-11-07 | Sanofi Sa | Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention |
| WO1988007553A1 (fr) * | 1987-03-26 | 1988-10-06 | Teijin Limited | Procede de preparation d'un complexe d'anticorps |
| EP0593452A1 (en) * | 1989-11-30 | 1994-04-27 | Mallinckrodt Medical, Inc. | Method for preparing a metal-radionuclide-labelled protein |
| US5194594A (en) * | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| SE9100142L (sv) * | 1991-01-17 | 1992-07-18 | Bengt Sandberg | En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal |
| CA2134239C (en) * | 1992-06-09 | 2004-11-23 | Donald B. Axworthy | Pretargeting methods and compounds |
| US5578287A (en) * | 1992-06-09 | 1996-11-26 | Neorx Corporation | Three-step pretargeting methods using improved biotin-active agent |
| JPH0853499A (ja) * | 1994-08-10 | 1996-02-27 | Green Cross Corp:The | キメラ抗体Ｆａｂ断片のオリゴマー体 |
-
1997
- 1997-01-06 JP JP9525384A patent/JP2000503301A/ja active Pending
- 1997-01-06 WO PCT/US1997/000307 patent/WO1997025069A1/en not_active Ceased
- 1997-01-06 CA CA002242750A patent/CA2242750C/en not_active Expired - Fee Related
- 1997-01-06 AU AU16939/97A patent/AU730388B2/en not_active Ceased
- 1997-01-06 KR KR1019980705339A patent/KR100485240B1/ko not_active Expired - Fee Related
- 1997-01-06 AT AT97902867T patent/ATE249243T1/de active
- 1997-01-06 ES ES97902867T patent/ES2206683T3/es not_active Expired - Lifetime
- 1997-01-06 DE DE69724761T patent/DE69724761T2/de not_active Expired - Lifetime
- 1997-01-06 RU RU98115277/15A patent/RU2219949C2/ru not_active IP Right Cessation
- 1997-01-06 EP EP97902867A patent/EP0873139B1/en not_active Expired - Lifetime
-
2012
- 2012-02-08 JP JP2012024825A patent/JP2012131808A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cędrowska et al. | Trastuzumab conjugated superparamagnetic iron oxide nanoparticles labeled with 225AC as a perspective tool for combined α-radioimmunotherapy and magnetic hyperthermia of HER2-positive breast cancer | |
| Omarini et al. | Pneumonitis and pulmonary fibrosis associated with breast cancer treatments | |
| JP2013511288A5 (enExample) | ||
| ES2655998T3 (es) | Anticuerpo dirigido contra el antígeno carcinoembrionario y usos del mismo | |
| IL266893A (en) | Meditopes and meditope-binding antibodies and uses thereof | |
| HRP20180507T1 (hr) | Identifikacija antigena povezanih s tumorom za dijagnozu i terapiju | |
| BR112012011268A2 (pt) | anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| Idrissou et al. | Targeted radionuclide therapy using auger electron emitters: the quest for the right vector and the right radionuclide | |
| ME02806B (me) | Protutijela protiv csf-1r | |
| EA201000910A1 (ru) | Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения | |
| HRP20210582T1 (hr) | Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe | |
| SI2533817T1 (en) | Target complexes that emit alpha particles containing thorium radionuclide and a ligand containing hydroxypyridinone | |
| Offenhäuser et al. | EphA3 pay-loaded antibody therapeutics for the treatment of glioblastoma | |
| JP2013506428A5 (enExample) | ||
| JP2018532689A5 (enExample) | ||
| Milenic et al. | Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease | |
| Wu et al. | Functionalized Hybrid Iron Oxide–Gold Nanoparticles Targeting Membrane Hsp70 Radiosensitize Triple-Negative Breast Cancer Cells by ROS-Mediated Apoptosis | |
| JP2014507435A5 (enExample) | ||
| Khalid et al. | Radiolabelled aptamers for theranostic treatment of cancer | |
| Sudo et al. | Preclinical evaluation of podoplanin-targeted alpha-radioimmunotherapy with the novel antibody NZ-16 for malignant mesothelioma | |
| Sharma et al. | Immuno-PET imaging of tumour PD-L1 expression in glioblastoma | |
| Trencsényi et al. | Targeted radium alpha therapy in the era of nanomedicine: in vivo results | |
| BR112013023211A2 (pt) | ensaio diagnóstico de anticorpos | |
| Csikos et al. | In vivo preclinical assessment of the VEGF targeting potential of the newly synthesized [52Mn] Mn-DOTAGA-Bevacizumab using experimental cervix carcinoma mouse model |